Mednet Logo
HomeMedical OncologyQuestion

How do you approach patients with unresectable NSCLC planned for concurrent chemoradiation who develop a serious infusion reaction to paclitaxel?

1
1 Answers
Mednet Member
Mednet Member
Medical Oncology · Roswell Park Comprehensive Cancer Center

There are a number of options to consider:

1. Platinum-etoposide is a well-established regimen and alternative standard for concurrent chemoradiation for many years.

2. For patients with nonsquamous histology, while the PROCLAIM study did not meet its study endpoint showing superiority compared to cis...

Register or Sign In to see full answer